A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memoral Sloan Kettering Basking Ridge
-
Middletown, New Jersey, United States, 07748
- Memoral Sloan Kettering Monmouth
-
Montvale, New Jersey, United States, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Harrison, New York, United States, 10604
- Memoral Sloan Kettering Westchester
-
New York, New York, United States, 10021
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age greater than or equal to 18 years.
Histopathologically confirmed diagnosis of one the following cancer types:
- Squamous cell carcinoma
- Esthesioneuroblastoma
- Adenoid cystic carcinoma
- Adenocarcinoma
Paranasal sinus/nasal cavity malignancy is considered unresectable with negative margins surgery or resection would be considered excessively morbid. This could include lesions with:
- Carotid involvement
- Cavernous sinus invasion
- Brain invasion
- Orbital apex
- Intraconal space
- Pterygoid musculature involvement
- Invasion of the clivus
- Resection of at least 80% of the volume of the tumor is feasible. Resectability will be determined by the surgeon and radiologist after discussion among the multidisciplinary team. For patients who have had surgery at an outside institution, the same parameters will be thoroughly screened to ensure the patient met the same inclusion criteria and resection standards.
- Patients must be a candidate for surgery (as per treating surgeon) and be able to tolerate proton radiation and chemotherapy (as per treating radiation oncologist and medical oncologist).
- Karnofsky performance statue >/= 70
The subject has organ and marrow function and laboratory values rendering safe administration of Cisplatin:
- The ANC >/= 1000/mm3 without colony stimulating factor support
- Platelets >/= 100,000/mm3
- Hemoglobin >/= 9 g/dL
- Bilirubin </= 1.5 mg/dL the ULM. For subjects with Gilbert's disease, bilirubin </= 3.0 mg/dL
- Serum albumin >/= 2.8 g/dl
- Creatinine clearance (CrCl) >/= 60 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:
- Male: CrCl (mL/min) = (140 = age) x wt (kg) / (serum creatinine x 72)
- Female: Multiply above result by 0.85
- ALT and AST </= 3.0 ULN
- Serum phosphorus, calcium, magnesium and potassium >/= LLN
- No evidence of intercurrent infection
- Negative pregnancy test for women of childbearing potential (<51 years of age) as per institutional policy.
- Patients with distant metastatic disease may not be included.
- Patient must be able to read and write in English.
- Patients who intitially meet the histopathological inclusion criteria but surgical pathology report shows Sinonasal Undifferentiated Carcinoma.
Exclusion Criteria:
- Tumor is deemed to be resectable with negative margins by conventional surgical standards.
- Patients not able to receive standard-dose cisplatin based on the judgement of the treating medical oncologist.
Patients with chronic kidney disease (GFR <60), uncontrolled hypertension, congestive heart failure, pre-existing bone marrow dysfunction, or cytopenias.
° Congestive heart failure (CHF): New York Heart Association (NYHA) Class II-IV at the time of screening
- Concurrent uncontrolled hypertension defined as sustained blood pressure > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; If severe hearing impairment is measured or if significant neuropathy is reported at baseline the treating physician will discuss the risks for further permanent hearing loss and neuropathy with the patient.
- Patients not able to have a MRI (due to pacemaker, claustrophobia, etc.).
- Inability to return to MSKCC for frequent scheduled hydration sessions post-chemotherapy.
- Inability to comply with requirements for cisplatin administration anti-emetic regimens post-treatment.
- Patients not able or unwilling to travel for proton therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Unresectable paranasal sinus/nasal cavity malignancy
|
Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles.
100 mg/m^2 (dose reductions after the first cycle allowed for toxicity)
Proton therapy treatment will follow the National Cancer Institute's "Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials".
Proton therapy techniques may include passively scattered or scanning or pencil beam technology.
In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner.
Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy.
The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2.
Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
Time Frame: 1 year
|
Assessment of local control after near-total endoscopic resection (NTR) followed by concurrent chemotherapy with proton-beam radiation in unresectable tumors (which we define as expected inability to perform negative margin surgery) of the paranasal sinuses and nasal cavity.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marc Cohen, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Carcinoma
- Nose Diseases
- Otorhinolaryngologic Diseases
- Otorhinolaryngologic Neoplasms
- Paranasal Sinus Diseases
- Nose Neoplasms
- Adenocarcinoma
- Paranasal Sinus Neoplasms
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Etoposide
- Cisplatin
Other Study ID Numbers
Other Study ID Numbers
- 17-442
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.